An observational study in Atrophic Scar, sponsored by CellinCells. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by CellinCells · Observational
CIC101-02-LT is a long-term follow-up study of participants treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101.
The long-term safety of TRTP-101 was evaluated by participants in clinical trial CIC101-02 and followed up for 5 years for serious adverse events.
611 studies on the registry are indexed under Cicatrix; 114 are open to participants now.
This study's planned enrollment of 31 is below the median of 80 across 67 observational studies indexed under Cicatrix.
Browse Cicatrix studies →CellinCells is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults with Atrophic Scars Treated with TRTP-101 in Study CIC101-02
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Serious Adverse Event
SAE will be collected
Time frame: Up to 5 years
Mean percent change in atrophic scar volume
The depressed volume of atropic scar is measured at baseline in study CIC101-02
Time frame: 6 (only Phase 1 participants), 12, 18 and 24 months
Patient's Satisfaction
Patient's Satisfaction with treatment scored by a 100-mm VAS(Visual Analogie Scale). On this scale, 0 indicates no satisfaction and 100 indicate extreme satisfaction.
Time frame: 6 (only Phase 1 participants), 12, 18 and 24 months
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CellinCells